《肿瘤学》
Hepatocellular carcinoma in elderly patients: a concise review on systemic therapy with sorafenib
发表时间：2015-11-10 浏览次数：1310次
引 用：
Giuseppe L, Alessandro V, Lonardi S, Luisa B, Ardi P, Valentina M, Gino C, Camil
关 键 词：
作者：
Lombardi Giuseppe1, Vitale Alessandro2, Sara Lonar
作者单位：
1 Department of Clinical and Experimental Oncology
出版年份：
2015
期刊页数：
58-62
收录者：
其他外文数据库
摘要：
The treatment of hepatocellular carcinoma (HCC) in elderly patients is unclear. In particular, the efficacy and safety of sorafenib as a systemic treatment in these patients is still under debate. We performed a concise review of sorafenib therapy in this population. However, it is important to make any decisions on treatment for elderly patients with HCC through a multidisciplinary team that includes experts in the liver disease. Patients with good clinical conditions should be treated with sorafenib.
